HKEX Insider Activity — 2026-07-23

by hk-insider-activities-daily

🇭🇰 HKEX DI Report — 2026-07-23

🟢 ACCUMULATING — 916 China Longyuan Power ← BlackRock, 7.40% (increased by 1.05pp from prior filing), bought 34,622,000 shares @ avg HKD 5.30 for HKD 183.5M Read: BlackRock pressed its stake in China's largest wind-power generator to 7.4%, committing HKD 183M on-exchange as state-mandated renewable-capacity targets continue to drive sector earnings.

🟢 ACCUMULATING — 586 China Conch Venture ← Anhui Conch Group / Wuhu Haichuang Industrial (consolidated group, three entities filing in chain), 20.71% (increased by 0.83pp from prior filing), bought 14,863,000 shares @ avg HKD 8.53 for HKD 126.8M Read: Three entities in the Anhui Conch parent chain filed in tandem under chain-of-control disclosure rules as the group added to its already-dominant 20%-plus position in this environmental and venture holdings company.

🟢 ACCUMULATING — 9688 Zai Lab ← JPMorgan Chase & Co., 9.75% (increased by 0.95pp from prior filing) Read: Although the disclosure was triggered by an off-exchange sale in one JPMorgan book, the firm's aggregate net long across all entities rose nearly 1pp, reflecting net buying elsewhere in this HK–US dual-listed oncology biotech.

🆕 NEW ENTRY — 9878 Huitongda Network ← Infini Global Master Fund, 16.56% (first reportable position), bought 87,757,544 shares @ avg HKD 6.56 for HKD 575.7M Read: Infini Global disclosed a cornerstone-sized 16.56% stake in this rural-commerce and goods-distribution platform in a single filing event, instantly becoming one of its largest outside shareholders.

🆕 NEW ENTRY — 1519 J&T Global Express ← JPMorgan Chase & Co. (2026-07-17 filing), 5.15% (increased by 0.43pp from prior sub-5% position), bought 37,249,716 shares @ avg HKD 9.20 for HKD 342.8M Read: A JPMorgan sub-entity filed a "ceased notifiable interest" form while the bank's group-aggregate long crossed 5%, establishing JPMorgan as a fresh substantial shareholder in this cross-border parcel logistics company via an intra-group reallocation.

🆕 NEW ENTRY — 9963 Transtech Optelecom Science ← OPTEL TECHNOLOGY LIMITED, 13.92% (first reportable position), bought 48,367,000 shares @ avg HKD 1.85 for HKD 89.5M Read: OPTEL Technology disclosed a 13.92% strategic bloc in Transtech Optelecom — a probable industry tie-up or consolidation play between these two optical-telecoms names given the scale and related-sector profile.

🆕 NEW ENTRY — 3696 InSilico Medicine ← JPMorgan Chase & Co., 5.17% (increased by 0.35pp), bought 2,007,000 shares @ avg HKD 44.82 for HKD 89.9M Read: A JPMorgan entity ceased its standalone notifiable interest while the group aggregate edged above 5%, establishing JPMorgan as a new substantial shareholder in this AI drug-discovery company through an intra-group reallocation.

🆕 NEW ENTRY — 1187 Cofoe Medical Technology ← Changsha Medical Investment Co., 6.66% (first reportable position), bought 1,797,400 shares @ avg HKD 30.18 for HKD 54.2M Read: A Changsha-based medical investment vehicle anchored a fresh 6.66% position in Cofoe Medical's H-shares, signalling strategic intent in this point-of-care diagnostics specialist.

🆕 NEW ENTRY — 568 Shandong Molong Petroleum Machinery ← Barclays PLC, 6.49% (first reportable position, increased by 2.40pp from prior sub-5% holding), bought 6,152,400 shares @ avg HKD 5.90 for HKD 36.3M Read: Barclays' prime-brokerage activity pushed its aggregate long above the disclosure threshold in this niche oilfield-equipment manufacturer, lifting the position to 6.49%.

🆕 NEW ENTRY — 8168 Amasse Capital Holdings ← Xudong Xie, 6.37% (first reportable position, increased by 2.43pp from prior sub-5% holding) Read: Individual investor Xudong Xie crossed the 5% disclosure threshold in this GEM-listed investment holding company, accumulating a 6.37% stake as at 2026-07-09 with no transaction price disclosed.

🆕 NEW ENTRY — 6821 Asymchem Laboratories (H) ← China Southern Asset Management, 5.09% (first reportable position, increased by 0.39pp from prior sub-5% holding), bought 109,700 shares @ avg HKD 120.18 for HKD 13.2M Read: China Southern Asset Management's fund inflows nudged it just past the 5% reporting line in Asymchem's H-shares, a CDMO/CRO recovery play as China's biopharma contract-outsourcing volumes rebuild.

🆕 NEW ENTRY — 1072 Dongfang Electric Corporation (H) ← Bank of America Corporation, 5.07% (increased by 0.45pp), acquired 1,821,240 shares (long) Read: A BofA sub-entity filed a "ceased notifiable interest" form while the bank's group-level aggregate long grew and held above 5%, pointing to an intra-group reallocation rather than a genuine exit from this state-owned power-equipment maker.

🏢 BUYBACK — 300 Midea Group (H) ← JPMorgan Chase & Co. (passive % change from issuer repurchase), 13.28% (decreased by 1.21pp from prior filing) Read: Midea's active repurchase programme triggered a reportable change in JPMorgan's proportional stake; the combined effect of the company's buyback and concurrent JPMorgan selling cut their holding 1.21pp to 13.28%.

🏢 BUYBACK — 6680 JL Mag Rare-Earth (H) ← JPMorgan Chase & Co. (passive % change from issuer repurchase), 6.32% (decreased by 1.02pp from prior filing) Read: JL Mag's share repurchase shrank the float and triggered this disclosure; JPMorgan's effective stake dipped 1.02pp as the denominator contracted and their absolute holdings were trimmed in parallel.

🔵 MAINTENANCE — Securities-lending pool reclassifications (prime-brokerage bookkeeping, not directional trades): • 1519 J&T Global Express — JPMorgan (reason 1704), 4.54% (decreased by 0.61pp) • 1432 China Shengmu Organic Milk — BPEA Private Equity (reason 1704), 0.00% (decreased by 6.40pp) • 6127 JOINN Laboratories (H) — Barclays (reason 1704), 2.74% (decreased by 3.81pp) • 2338 Weichai Power (H) — JPMorgan (reason 16021-L, probable securities-lending reclassification code), 9.30% (increased by 0.83pp) Read: All four entries reflect shares shifting between long and prime-brokerage lending-pool buckets at the custodian level — including the dramatic 6.40pp swing at China Shengmu — and none represents a directional investment decision by the filer.